AETHLON MEDICAL INC (AEMD) is a publicly traded Healthcare sector company. As of May 21, 2026, AEMD trades at $2.07 with a market cap of $3.20M and a P/E ratio of -0.24. AEMD moved +0.49% today. Year to date, AEMD is -24.73%; over the trailing twelve months it is -93.69%. Its 52-week range spans $1.36 to $84.40. Rallies surfaces AEMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
DSMB Clears Aethlon Hemopurifier for Third Cohort After Safety Review: The DSMB overseeing AEMD-2022-06 recommended advancement to the third cohort after finding no safety concerns with the Hemopurifier device or procedure. Enrollment is open for three treatments over one week in Australia, targeting nine to eighteen patients with solid tumors receiving Pembrolizumab or Nivolumab.
| Metric | Value |
|---|---|
| Price | $2.07 |
| Market Cap | $3.20M |
| P/E Ratio | -0.24 |
| EPS | $-8.58 |
| Dividend Yield | 0.00% |
| 52-Week High | $84.40 |
| 52-Week Low | $1.36 |
| Volume | 294 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-13.39M |
| Gross Margin | 0.00% |
AEMD analyst coverage data. Average price target: $0.00.